
Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Panelists discuss how early detection of chronic kidney disease (CKD) in stages 2 and 3 can improve patient outcomes across various specialties, including nephrology, cardiology, and primary care.






